You are here

FDA Update

Congress’ Remedy for Post-marketing Woes Might Not Be a Cure

Stephen Barlas
PDF version: 
The new PDUFA bill might not be strong enough to overcome the weaknesses of the current system of post-marketing surveillance of new drugs.